Abstract
Population-based studies have established that long-term intake of non-steroidal anti-inflammatory drugs (NSAIDs), compounds that inhibit the enzymatic activity of cyclooxygenase (COX), reduces the relative risk for developing colorectal cancer. These studies led to the identification of a molecular target, COX-2, that is involved in tumour promotion during colorectal cancer progression. Recent studies in humans indicate that therapy with specific COX-2 inhibitors might be an effective approach to colorectal cancer prevention and treatment.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Colorectal Neoplasms / drug therapy
-
Colorectal Neoplasms / enzymology
-
Colorectal Neoplasms / prevention & control*
-
Cyclooxygenase 2
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors / therapeutic use*
-
Disease Models, Animal
-
Humans
-
Isoenzymes / antagonists & inhibitors*
-
Isoenzymes / physiology
-
Membrane Proteins
-
Prostaglandin-Endoperoxide Synthases / physiology
-
Prostaglandins / biosynthesis
-
Receptors, Prostaglandin E / physiology
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase 2 Inhibitors
-
Cyclooxygenase Inhibitors
-
Isoenzymes
-
Membrane Proteins
-
Prostaglandins
-
Receptors, Prostaglandin E
-
Cyclooxygenase 2
-
PTGS2 protein, human
-
Prostaglandin-Endoperoxide Synthases